CD247 and neoplasm: Notably, they found that in vitro and in vivo anti-tumour activity of iPSC-NK cells that expressed an NK cell-optimised CAR (e.g., NKG2D transmembrane domain followed by a fusion of 2B4 and CD3ζ endodomains) outperformed iPSC-NK cells that expressed a traditional T-cell-optimised third generation CAR (e.g., linear endodomain comprising CD28, 4-1BB and CD3ζ) (Li et al. 2018).